ALS treatment tazbentetol gets FDA fast track status

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to tazbentetol, an experimental oral therapy being developed by Spinogenix for amyotrophic lateral sclerosis (ALS). Fast-track status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. It will allow Spinogenix…

As soon as I reached for the sock, I knew it would fall to the floor. And it did. I retrieved it by slowly bending sideways in my chair, stretching my arm in its direction, and with a mighty oomph, finally seized the soft fabric. That was just one speed…

Acurastem has received $7.5 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance AS-241, its lead clinical candidate for amyotrophic lateral sclerosis (ALS) and related diseases, toward clinical trials. The grant was supported by cell-based studies showing that AS-241 can restore certain ALS-related defects…

Following a recent meeting with the U.S. Food and Drug Administration (FDA), Clene is planning to submit an application asking the agency to approve its experimental therapy CNM-Au8 as a treatment for amyotrophic lateral sclerosis (ALS). The company specifically plans to file a new drug application (NDA)…

People with amyotrophic lateral sclerosis (ALS) who received a high dose of the experimental therapy dazucorilant had a significantly higher chance of survival than patients given a lower dose or no treatment. That’s according to new analyses of data from the DAZALS Phase 2 clinical trial (NCT05407324), which…

May is ALS Awareness Month, and in the U.S. and around the world, organizations are educating, sponsoring events, and encouraging the community to join them in taking action, providing financial support, and pushing for better access to care through advocacy for those living with amyotrophic lateral sclerosis. The…

After my husband, Todd, got ALS and I became his caregiver, I turned to reading and writing as a way to cope. Reading helps me make sense of life, or sometimes just step outside of my life for a while. Writing helps me sort through what I’m thinking and…

Vectory Therapeutics has been given a green light to expand its first-in-human clinical trial of VTx-002, its treatment candidate for amyotrophic lateral sclerosis (ALS), to sites in the U.K. and the European Union. The Phase 1/2 PIONEER-ALS study (NCT07287397) is already underway in the U.S., and is…

In France, the average family impacted by amyotrophic lateral sclerosis (ALS) has to pay thousands in out-of-pocket expenses to cover such things as mobility aids and paid caregivers — and because patients and caregivers often need to stop working to manage the disease, these expenses pile up on top…

RAG-17, an experimental treatment Ractigen Therapeutics is developing for people with amyotrophic lateral sclerosis (ALS) who carry a SOD1 mutation (SOD1-ALS), was well tolerated at multiple doses and led to profound changes in disease biomarkers, preliminary trial data showed. The data cover the first part of an ongoing…